Page last updated: 2024-08-16

rabeprazole and brivanib

rabeprazole has been researched along with brivanib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M	1

Other Studies

1 other study(ies) available for rabeprazole and brivanib

Article	Year
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Molecular cancer therapeutics, 2013, Volume: 12, Issue:2 Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Mice; Mice, Nude; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Rabeprazole; Random Allocation; Sunitinib; Triazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2013

Article

Year

The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.

Molecular cancer therapeutics, 2013, Volume: 12, Issue:2

Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Mice; Mice, Nude; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Rabeprazole; Random Allocation; Sunitinib; Triazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2013